Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.23
+0.38 (3.21%)
At close: Feb 6, 2026, 4:00 PM EST
12.47
+0.24 (1.96%)
After-hours: Feb 6, 2026, 7:07 PM EST

Cullinan Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-216.81-167.38-153.16111.21-65.57-51.8
Depreciation & Amortization
0.310.310.310.090.050.06
Loss (Gain) From Sale of Assets
----276.86--
Asset Writedown & Restructuring Costs
--0.44--6.45
Loss (Gain) From Sale of Investments
-8.89-15.47-10.151.43.10.23
Stock-Based Compensation
38.3637.8230.4427.9624.3814.91
Other Operating Activities
--0.19-1.94-2.02-1.85-6.48
Change in Accounts Payable
-0.39-0.81-0.17-0.51-4.845.58
Change in Income Taxes
---4.284.28--
Change in Other Net Operating Assets
13.160.424.117.41.291.27
Operating Cash Flow
-174.27-145.3-134.28-126.66-43.43-29.77
Capital Expenditures
-0.04--0.21-1.13--0.01
Sale of Property, Plant & Equipment
---0.09--
Divestitures
---275--
Investment in Securities
173.6-136.3136.01-24.98-333.78-6.86
Other Investing Activities
-----1.45
Investing Cash Flow
173.56-136.3135.81248.98-333.78-5.42
Short-Term Debt Issued
--1.832.38--
Total Debt Issued
--1.832.38--
Short-Term Debt Repaid
----2.2--
Total Debt Repaid
----2.2--
Net Debt Issued (Repaid)
--1.830.18--
Issuance of Common Stock
1.96270.6438.936.02270.55145.51
Other Financing Activities
--4.45--32.13-1.77-5.37
Financing Cash Flow
1.96266.1940.75-25.93268.78140.14
Net Cash Flow
1.25-15.43-57.7296.38-108.42104.95
Free Cash Flow
-174.31-145.3-134.48-127.8-43.43-29.78
Free Cash Flow Margin
-----229.28%-
Free Cash Flow Per Share
-2.96-2.70-3.24-2.74-1.01-1.50
Cash Income Tax Paid
--2.27-4.4337.8--
Levered Free Cash Flow
-99.32-84.86-88.76-47.6-24.64-11.56
Unlevered Free Cash Flow
-99.32-84.86-88.76-47.6-24.64-11.56
Change in Working Capital
12.76-0.39-0.3411.18-3.546.85
Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q